Skip to main content
Michael Rosen, MD, Pediatric Gastroenterology, Palo Alto, CA, Lucile Packard Children's Hospital Stanford

MichaelRosenMDMSCI

Pediatric Gastroenterology Palo Alto, CA

Pediatric Inflammatory Bowel Disease Gastroenterology

Stanford University Endowed Professor for Pediatric IBD and Celiac Disease

Dr. Rosen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rosen's full profile

Already have an account?

Education & Training

  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterFellowship, Pediatric Gastroenterology, 2006 - 2009
  • Vanderbilt School of Medicine
    Vanderbilt School of MedicineMSc, 2009
  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterResidency, Pediatrics, 2003 - 2006
  • Harvard Medical School
    Harvard Medical SchoolClass of 2003
  • Duke University
    Duke UniversityBS, Biology, Summa Cum Laude, 1995 - 1999
  • Duke University
    Duke UniversityBS, Biology, Summa Cum Laude, 1999

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2021 - 2025
  • OH State Medical License
    OH State Medical License 2013 - 2022
  • KY State Medical License
    KY State Medical License 2020 - 2022
  • WI State Medical License
    WI State Medical License 2016 - 2021
  • TN State Medical License
    TN State Medical License 2009 - 2015
  • American Board of Pediatrics Pediatric Gastroenterology

Awards, Honors, & Recognition

  • Clinical Team Achievement Faculty Award CCHMC, 2018
  • Elected Member Society for Pediatric Research, 2014
  • Turner-Hazinski Research Award Dept. of Pediatrics, Vanderbilt Univ. Sch. of Medicine, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Mucosal type 2 and type 17 gene expression distinguishes ulcerative colitis from colon-only Crohn�s disease in treatment-na�ve pediatric patients  
    Rosen MJ, Karns R, Vallance JE, Bezold R, Waddell A, Collins MH, Haberman Y, Minar P, Baldassano RN, Hyams JS, Baker SS, Kellermayer R, Noe J, Griffiths AM, Rosh JR, C..., Gastroenterology, 1/1/2017
  •  
    Liu Z, Kong F, Vallance JE, Harmel-Laws E, Amarachintha S, Steinbrecher KA, Rosen MJ, Bhattacharyya S., Physiological Reports., 1/1/2017
  • Microbiota-sensitive epigenetic signature predicts inflammation in Crohn�s disease  
    Kelly D, Kotliar M, Woo V, Jagannathan S, Whitt J, Moncivaiz J, Aronow BJ, Dubinsky MC, Hyams JS, Markowitz JF, Baldassano RN, Stephens MC, Walters TD, Kugathasan S, H..., JCI Insight, 1/1/2017
  • Join now to see all

Abstracts/Posters

  • The treatment na�ve rectal transcriptome identifies pathways mediating clinical and endoscopic severity and response to initial therapy in pediatric ulcerative colitis.
    Haberman Y, Karns R, Dexheimer PJ, Bauman LE, Collins MH, Rosen MJ, et al., AGA Annual Scientific Meeting at DDW, Washington, DC, 1/1/2018
  • IL-33 indirectly induces goblet cell hyperplasia in the murine intestine through IL-13 production by type 2 innate lymphoid cells.
    Waddell AP, Vallance JE, Rosen MJ., AGA Abstracts published in Gastroenterology, 1/1/2017
  • Effect of an Anti-TNF Therapeutic Drug Monitoring Quality Improvement Program on Inflammatory Bowel Disease Patient Outcomes at a Large Academic Pediatric Gastroentero...
    Mulgund AA, Bauman L, Chona DL, Sharma P, Su W, Fei L, Denson LA, Minar P, Dykes DM, Rosen MJ., World Congress of Gastroenterology at ACG, NASPGHAN Annual Scientific Meeting, 1/1/2017
  • Join now to see all

Lectures

  • Cases from the Wards 
    Children�s Hospital Boston - 1/1/2005
  • Interleukin-33 in Ulcerative Colitis: Pro-Inflammatory Cytokine or Protective Response 
    Cincinnati, OH - 1/10/2015
  • Mucosal type 2 and type 17 gene expression distinguishes ulcerative colitis from colitis-only Crohn�s disease in treatment-na�ve pediatric patients 
    Mt. Sterling, OH - 1/9./2016
  • Join now to see all

Other

  • Outcome following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant inflammatory bowel disease. 
    Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, Schwartz DA, Wilson KT, Rosen MJ., Biologic Treatment of Pediatric Inflammatory Bowel Disease: A Decade of JPGN Contributions
    1/1/2014

Professional Memberships

Hospital Affiliations